CytoReason Revenue and Competitors

Israel

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • CytoReason's estimated annual revenue is currently $33.8M per year.(i)
  • CytoReason's estimated revenue per employee is $201,000

Employee Data

  • CytoReason has 168 Employees.(i)
  • CytoReason grew their employee count by 24% last year.

CytoReason's People

NameTitleEmail/Phone
1
VP R&DReveal Email/Phone
2
Project ManagerReveal Email/Phone
3
Strategic ConsultantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$16.7M83-34%$237MN/A
#2
$7.8M39-2%N/AN/A
#3
$33.8M16824%N/AN/A
#4
$11.3M5619%N/AN/A
#5
$10.3M51-12%N/AN/A
#6
$11.7M581060%N/AN/A
#7
$9.6M4841%N/AN/A
Add Company

What Is CytoReason?

CytoReason turns human clinical data into clear biology, to deliver data-driven target discovery and drug development. CytoReason?s access to unmatched proprietary and public data, combined with cutting-edge machine learning technologies, creates our unique biological models of disease, tissue and drug. Using our molecular-level disease models we turn human clinical data into biology, mapping what the cells, genes and proteins are doing in a disease, tissue and treatment environment. This enables us to uncover disease and drug mechanisms of action and turn that biology into clinical edge, by delivering valuable IP in the form of novel targets, indications, combinations and biomarkers.

keywords:N/A

N/A

Total Funding

168

Number of Employees

$33.8M

Revenue (est)

24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CytoReason News

2022-04-13 - CytoReason forms partnership with Helixrus, expanding into Asia

The partnership will see Helixrus represent CytoReason's AI platform and professional services in the Korean market.

2022-04-13 - CytoReason expands reach in Asia, leveraging ML in drug ...

Israel's CytoReason, a leading developer of computational disease models for efficient drug discovery and development, has announced the...

2022-04-06 - Israel's CytoReason, S. Korea's Helixrus partner on machine ...

CytoReason, a developer of computational disease models for efficient drug discovery and development, has signed a commercial partnership...

2021-05-19 - CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology USA - English USA - English

TEL AVIV, Israel, May 19, 2021 /PRNewswire/ -- CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to ...

2019-01-07 - CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery

TEL AVIV, Israel–(BUSINESS WIRE)–January 7, 2019– CytoReason, a leader in machine learning for drug discovery and development, announced today that it has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE) that will leverage CytoReason’s cell-centered models of the immune system ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$53.6M1684%N/A
#2
$15M1686%N/A
#3
$60.6M1686%N/A
#4
$45.3M1686%N/A
#5
$18.5M168N/AN/A